Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Erik Hillo Lørup"'
Publikováno v:
British Journal of Dermatology. 188:372-379
BackgroundComorbidities associated with psoriasis are well documented. However, few studies have explored the comorbidity trajectories that patients with psoriasis commonly experience over time. This study reports the 5-year comorbidity trajectories
Autor:
Alexander Egeberg, Nana Aviaaja Lippert Rosenø, David Aagaard, Erik Hillo Lørup, Mia-Louise Nielsen, Lea Nymand, Lars Erik Kristensen, Jacob P. Thyssen, Simon Francis Thomsen, Rene Lindholm Cordtz, Nikolai Loft, Lone Skov, Lars Erik Bryld, Mads Kirchheiner Rasmussen, Pil Højgaard, Salome Kristensen, Lene Dreyer
Publikováno v:
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M-L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M-L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, pp. 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M-L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, pp. 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
OBJECTIVE: Drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA), and psoriasis. The objective of this study
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB59